Combination therapy with or without amino acid supplement for advanced liver cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of two drugs, lenvatinib and pembrolizumab, with or without a branched-chain amino acid (BCAA) supplement, for people with advanced liver cancer that cannot be removed by surgery. The study aims to see if adding the supplement improves outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 74 years old.
- You have been diagnosed with hepatocellular carcinoma (the most common type of liver cancer) that cannot be removed surgically.
- Your cancer is at a stage where it has spread within the liver or to nearby areas (BCLC stage B or C).
- You have not had prior treatment with targeted therapies (like sorafenib or lenvatinib) or immunotherapies (like PD-1/PD-L1 inhibitors).
- You are generally healthy enough to carry out daily activities (ECOG performance status 0 or 1).
- Your liver and kidney function are within acceptable limits, and you do not have severe bleeding risk.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a combination of two drugs (tislelizumab and lenvatinib) given before surgery can lower the risk of liver cancer coming back in people with early-stage but high-risk disease.
This trial tests a combination of four treatments (two immunotherapy drugs, a blood-vessel-blocking drug, and chemotherapy delivered directly to the liver) to shrink unresectable (inoperable) advanced liver cancer and potentially make it removable by surgery. The goal is to help patients who have never had cancer treatment before.
This trial tests a combination of a procedure that delivers chemotherapy directly to the liver tumor (called TACE) with an oral targeted therapy drug (lenvatinib) for people with liver cancer that cannot be removed with surgery. The goal is to see if this combination can shrink tumors more effectively than TACE alone.
This trial tests a new drug called BL-B01D1, alone or together with other drugs, in people with advanced liver cancer that has not improved with other treatments. The goal is to see if these combinations can help shrink tumors or slow the cancer's growth.
This trial tests a combination of two drugs (lenvatinib and toripalimab, a type of immunotherapy) plus a special chemotherapy infusion directly into the liver artery for people with advanced liver cancer that has not been treated before. The goal is to see if adding the immunotherapy helps shrink tumors better than the standard combination.
This trial tests a combination of a focused radiation beam (SBRT) plus a pill that helps stop tumor blood vessel growth (lenvatinib) and a procedure that blocks blood flow to the tumor (TACE) for people with advanced liver cancer that has not yet spread outside the liver. The goal is to see if this triple therapy can improve outcomes without prior treatment.
Hear when a new HCC - Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.